TY - JOUR
T1 - Small Intestinal Bacterial Overgrowth in Children
T2 - A State-Of-The-Art Review
AU - Avelar Rodriguez, David
AU - Ryan, Paul Mac Daragh
AU - Toro Monjaraz, Erick Manuel
AU - Ramirez Mayans, Jaime Alfonso
AU - Quigley, Eamonn Martin
N1 - Publisher Copyright:
© Copyright © 2019 Avelar Rodriguez, Ryan, Toro Monjaraz, Ramirez Mayans and Quigley.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/9/4
Y1 - 2019/9/4
N2 - Small intestinal bacterial overgrowth (SIBO) is a heterogenous and poorly understood entity characterised by an excessive growth of select microorganisms within the small intestine. This excessive bacterial biomass, in turn, disrupts host physiology in a myriad of ways, leading to gastrointestinal and non-gastrointestinal symptoms and complications. SIBO is a common cause of non-specific gastrointestinal symptoms in children, such as chronic abdominal pain, abdominal distention, diarrhoea, and flatulence, amongst others. In addition, it has recently been implicated in the pathophysiology of stunting, a disease that affects millions of children worldwide. Risk factors such as acid-suppressive therapies, alterations in gastrointestinal motility and anatomy, as well as impoverished conditions, have been shown to predispose children to SIBO. SIBO can be diagnosed via culture-dependant or culture-independent approaches. SIBO's epidemiology is limited due to the lack of uniformity and consensus of its diagnostic criteria, as well as the paucity of literature available. Antibiotics remain the first-line treatment option for SIBO, although emerging modalities such as probiotics and diet manipulation could also have a role. Herein, we present a state-of-the-art-review which aims to comprehensively outline the most current information on SIBO in children, with particular emphasis on the gut microbiota.
AB - Small intestinal bacterial overgrowth (SIBO) is a heterogenous and poorly understood entity characterised by an excessive growth of select microorganisms within the small intestine. This excessive bacterial biomass, in turn, disrupts host physiology in a myriad of ways, leading to gastrointestinal and non-gastrointestinal symptoms and complications. SIBO is a common cause of non-specific gastrointestinal symptoms in children, such as chronic abdominal pain, abdominal distention, diarrhoea, and flatulence, amongst others. In addition, it has recently been implicated in the pathophysiology of stunting, a disease that affects millions of children worldwide. Risk factors such as acid-suppressive therapies, alterations in gastrointestinal motility and anatomy, as well as impoverished conditions, have been shown to predispose children to SIBO. SIBO can be diagnosed via culture-dependant or culture-independent approaches. SIBO's epidemiology is limited due to the lack of uniformity and consensus of its diagnostic criteria, as well as the paucity of literature available. Antibiotics remain the first-line treatment option for SIBO, although emerging modalities such as probiotics and diet manipulation could also have a role. Herein, we present a state-of-the-art-review which aims to comprehensively outline the most current information on SIBO in children, with particular emphasis on the gut microbiota.
KW - gut microbiota
KW - proton pump inhibitors
KW - small bowel bacterial overgrowth
KW - small intestinal bacterial overgrowth
KW - small intestine bacterial overgrowth
KW - stunting
UR - http://www.scopus.com/inward/record.url?scp=85072879773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072879773&partnerID=8YFLogxK
U2 - 10.3389/fped.2019.00363
DO - 10.3389/fped.2019.00363
M3 - Review article
AN - SCOPUS:85072879773
SN - 2296-2360
VL - 7
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
M1 - 363
ER -